Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Metabolic profiling during HIV-1 and HIV-2 infection of primary human monocyte-derived macrophages.

Hollenbaugh JA, Montero C, Schinazi RF, Munger J, Kim B.

Virology. 2016 Apr;491:106-14. doi: 10.1016/j.virol.2016.01.023. Epub 2016 Feb 16.

2.

Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage.

Alteri C, Surdo M, Bellocchi MC, Saccomandi P, Continenza F, Armenia D, Parrotta L, Carioti L, Costa G, Fourati S, Di Santo F, Scutari R, Barbaliscia S, Fedele V, Carta S, Balestra E, Alcaro S, Marcelin AG, Calvez V, Ceccherini-Silberstein F, Artese A, Perno CF, Svicher V.

Antimicrob Agents Chemother. 2015 Aug;59(8):4870-81. doi: 10.1128/AAC.00137-15. Epub 2015 Jun 8.

3.

Effect of μ-opioid agonist DAMGO on surface CXCR4 and HIV-1 replication in TF-1 human bone marrow progenitor cells.

Strazza M, Banerjee A, Alexaki A, Passic SR, Meucci O, Pirrone V, Wigdahl B, Nonnemacher MR.

BMC Res Notes. 2014 Oct 23;7:752. doi: 10.1186/1756-0500-7-752.

4.

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).

Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, Paul R, Zhang G, Ho E, Hanks N, Nakamoto B, Shiramizu BT, Shikuma CM.

J Neurovirol. 2014 Dec;20(6):571-82. doi: 10.1007/s13365-014-0279-x. Epub 2014 Sep 17.

5.

The effects of opioids on HIV reactivation in latently-infected T-lymphoblasts.

Prottengeier J, Koutsilieri E, Scheller C.

AIDS Res Ther. 2014 Jul 2;11:17. doi: 10.1186/1742-6405-11-17. eCollection 2014.

6.

CD4 ligation on human blood monocytes triggers macrophage differentiation and enhances HIV infection.

Zhen A, Krutzik SR, Levin BR, Kasparian S, Zack JA, Kitchen SG.

J Virol. 2014 Sep 1;88(17):9934-46. doi: 10.1128/JVI.00616-14. Epub 2014 Jun 18.

7.

Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I.

Shah S, Alexaki A, Pirrone V, Dahiya S, Nonnemacher MR, Wigdahl B.

Virol J. 2014 May 16;11:92. doi: 10.1186/1743-422X-11-92.

8.

The expression of HIV-1 Vpu in monocytes causes increased secretion of TGF-β that activates profibrogenic genes in hepatic stellate cells.

Patel P, Khan N, Rani M, Gupta D, Jameel S.

PLoS One. 2014 Feb 13;9(2):e88934. doi: 10.1371/journal.pone.0088934. eCollection 2014.

9.

Transcriptome analysis of primary monocytes from HIV-positive patients with differential responses to antiretroviral therapy.

Wu JQ, Sassé TR, Saksena MM, Saksena NK.

Virol J. 2013 Dec 27;10:361. doi: 10.1186/1743-422X-10-361.

10.

Substance abuse, HIV-1 and hepatitis.

Parikh N, Nonnemacher MR, Pirrone V, Block T, Mehta A, Wigdahl B.

Curr HIV Res. 2012 Oct;10(7):557-71. Review.

11.

Constitutive gene expression in monocytes from chronic HIV-1 infection overlaps with acute Toll-like receptor induced monocyte activation profiles.

Gekonge B, Giri MS, Kossenkov AV, Nebozyhn M, Yousef M, Mounzer K, Showe L, Montaner LJ.

PLoS One. 2012;7(7):e41153. doi: 10.1371/journal.pone.0041153. Epub 2012 Jul 18.

12.

Cognitive performance related to HIV-1-infected monocytes.

Kusao I, Shiramizu B, Liang CY, Grove J, Agsalda M, Troelstrup D, Velasco VN, Marshall A, Whitenack N, Shikuma C, Valcour V.

J Neuropsychiatry Clin Neurosci. 2012 Winter;24(1):71-80. doi: 10.1176/appi.neuropsych.11050109.

13.

Replication-independent expression of anti-apoptosis marker genes in human peripheral blood mononuclear cells infected with the wild-type HIV-1 and reverse transcriptase variants.

Sharma PL, Chunduri H, Wise J, Mindley R, Rimland D.

Viral Immunol. 2012 Feb;25(1):12-20. doi: 10.1089/vim.2011.0057. Epub 2012 Jan 12.

14.

Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis.

Williams DW, Eugenin EA, Calderon TM, Berman JW.

J Leukoc Biol. 2012 Mar;91(3):401-15. doi: 10.1189/jlb.0811394. Epub 2012 Jan 6. Review.

15.

Mucosal and peripheral Lin- HLA-DR+ CD11c/123- CD13+ CD14- mononuclear cells are preferentially infected during acute simian immunodeficiency virus infection.

Moore AC, Bixler SL, Lewis MG, Verthelyi D, Mattapallil JJ.

J Virol. 2012 Jan;86(2):1069-78. doi: 10.1128/JVI.06372-11. Epub 2011 Nov 16.

16.

Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis.

Banerjee A, Strazza M, Wigdahl B, Pirrone V, Meucci O, Nonnemacher MR.

J Neurovirol. 2011 Aug;17(4):291-302. doi: 10.1007/s13365-011-0037-2. Epub 2011 Jul 7. Review.

17.

Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.

Marsden MD, Avancena P, Kitchen CM, Hubbard T, Zack JA.

Antimicrob Agents Chemother. 2011 Aug;55(8):3696-702. doi: 10.1128/AAC.00566-11. Epub 2011 May 31.

18.

Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.

Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, Sleasman JW, Goodenow MM.

AIDS. 2010 Jun 1;24(9):1281-90. doi: 10.1097/QAD.0b013e328339e228.

19.

Transcriptome analysis of monocyte-HIV interactions.

Van den Bergh R, Florence E, Vlieghe E, Boonefaes T, Grooten J, Houthuys E, Tran HT, Gali Y, De Baetselier P, Vanham G, Raes G.

Retrovirology. 2010 Jun 14;7:53. doi: 10.1186/1742-4690-7-53.

20.

Innate and adaptive factors regulating human immunodeficiency virus type 1 genomic activation.

Shah S, Nonnemacher MR, Pirrone V, Wigdahl B.

J Neuroimmune Pharmacol. 2010 Sep;5(3):278-93. doi: 10.1007/s11481-010-9207-x. Epub 2010 Apr 13. Review.

Items per page

Supplemental Content

Write to the Help Desk